Tidal Investments LLC Grows Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Tidal Investments LLC raised its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 25.2% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 17,621 shares of the medical equipment provider’s stock after purchasing an additional 3,547 shares during the period. Tidal Investments LLC’s holdings in Lantheus were worth $1,934,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Wilmington Savings Fund Society FSB bought a new position in shares of Lantheus during the 3rd quarter valued at approximately $25,000. Signaturefd LLC boosted its position in shares of Lantheus by 40.5% in the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after purchasing an additional 92 shares during the period. Nkcfo LLC purchased a new stake in shares of Lantheus in the second quarter worth $47,000. UMB Bank n.a. raised its position in shares of Lantheus by 42.1% during the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after purchasing an additional 126 shares during the period. Finally, Kathleen S. Wright Associates Inc. purchased a new position in shares of Lantheus during the 3rd quarter valued at $51,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. JMP Securities cut their price target on Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a research note on Thursday, November 7th. Redburn Atlantic initiated coverage on Lantheus in a research report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 target price for the company. Truist Financial reissued a “buy” rating and issued a $120.00 price target (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. Finally, StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $130.00.

Lantheus Price Performance

NASDAQ:LNTH opened at $93.48 on Tuesday. The company has a market cap of $6.50 billion, a price-to-earnings ratio of 15.55 and a beta of 0.45. Lantheus Holdings, Inc. has a 1 year low of $50.20 and a 1 year high of $126.89. The stock’s 50 day simple moving average is $97.62 and its two-hundred day simple moving average is $98.20.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.